Cytokinetics, Inc. Stock Nasdaq
Stocks
US23282W1009
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 11.16B 9.8B 9.03B 8.45B 15.84B 1,052B 16.18B 109B 42.02B 519B 41.9B 40.98B 1,804B | P/E 2026 * |
-12.7x | P/E 2027 * | -17.7x |
|---|---|---|---|---|---|
| Enterprise Value | 10.58B 9.29B 8.56B 8.01B 15.01B 997B 15.33B 103B 39.83B 492B 39.71B 38.84B 1,710B | EV / Sales 2026 * |
97.5x | EV / Sales 2027 * | 27.2x |
| Free-Float |
98.21% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytokinetics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 62 | 01/01/2007 |
Sung Lee
DFI | Director of Finance/CFO | 55 | 08/05/2024 |
Fady Malik
CTO | Chief Tech/Sci/R&D Officer | 61 | 13/11/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Blum
BRD | Director/Board Member | 62 | 01/01/2007 |
John Henderson
CHM | Chairman | 81 | 08/04/2022 |
Wendell Wierenga
BRD | Director/Board Member | 78 | 09/02/2011 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.33% | +1.37% | +64.03% | +119.11% | 55.63B | |
| +0.82% | +15.05% | +79.93% | +84.34% | 52.25B | |
| +1.36% | +0.36% | -14.06% | -14.69% | 23.07B | |
| -1.04% | +7.91% | +1.61% | +419.24% | 22.41B | |
| -0.18% | +7.20% | +32.16% | -14.07% | 17.32B | |
| -1.10% | +4.00% | +28.70% | -34.51% | 15.94B | |
| -3.35% | +8.96% | +132.20% | +290.18% | 13.47B | |
| +2.89% | +5.51% | +27.11% | +181.45% | 13.77B | |
| +1.31% | +0.53% | +28.62% | - | 12.43B | |
| Average | +0.12% | +4.78% | +42.26% | +128.88% | 25.14B | |
| Weighted average by Cap. | +0.26% | +5.13% | +48.50% | +120.17% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 109M 95.33M 87.84M 82.2M 154M 10.23B 157M 1.06B 409M 5.05B 407M 399M 17.54B | 389M 342M 315M 294M 552M 36.66B 564M 3.78B 1.46B 18.1B 1.46B 1.43B 62.86B |
| Net income | -806M -708M -652M -611M -1.14B -76B -1.17B -7.84B -3.04B -37.51B -3.03B -2.96B -130B | -653M -574M -528M -495M -927M -61.56B -947M -6.35B -2.46B -30.39B -2.45B -2.4B -106B |
| Net Debt | -583M -513M -472M -442M -828M -55.02B -846M -5.67B -2.2B -27.16B -2.19B -2.14B -94.34B | -601M -528M -486M -455M -852M -56.63B -871M -5.84B -2.26B -27.95B -2.26B -2.21B -97.1B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
